XOMA (NASDAQ:XOMA) Raised to “Buy” at Wall Street Zen

XOMA (NASDAQ:XOMA) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Saturday.

Other analysts also recently issued research reports about the company. Benchmark started coverage on XOMA in a research note on Thursday, April 17th. They issued a “buy” rating and a $35.00 price target on the stock. HC Wainwright reissued a “buy” rating and issued a $104.00 target price on shares of XOMA in a report on Wednesday, May 28th.

XOMA Stock Down 3.0%

NASDAQ:XOMA opened at $23.85 on Friday. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52. The firm’s 50-day moving average price is $23.91 and its 200-day moving average price is $24.58. The company has a market capitalization of $285.41 million, a PE ratio of -6.85 and a beta of 0.94. XOMA has a 1-year low of $18.35 and a 1-year high of $35.00.

XOMA (NASDAQ:XOMA) last posted its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.26) by $0.32. XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. The business had revenue of $15.91 million for the quarter, compared to analyst estimates of $6.75 million. On average, equities analysts predict that XOMA will post -1.41 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Joseph M. Limber acquired 17,935 shares of the stock in a transaction that occurred on Thursday, April 3rd. The shares were bought at an average price of $25.24 per share, for a total transaction of $452,679.40. Following the completion of the transaction, the director now directly owns 16,524 shares in the company, valued at approximately $417,065.76. This trade represents a -1,271.08% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CIO Bradley Sitko acquired 4,134 shares of XOMA stock in a transaction that occurred on Friday, March 21st. The shares were purchased at an average price of $23.89 per share, with a total value of $98,761.26. Following the transaction, the executive now owns 10,484 shares of the company’s stock, valued at $250,462.76. The trade was a 65.10% increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 29,312 shares of company stock valued at $735,061. Insiders own 9.10% of the company’s stock.

Hedge Funds Weigh In On XOMA

A number of hedge funds have recently modified their holdings of XOMA. Woodline Partners LP lifted its holdings in XOMA by 7.9% in the 1st quarter. Woodline Partners LP now owns 168,550 shares of the biotechnology company’s stock worth $3,359,000 after purchasing an additional 12,284 shares in the last quarter. Stonepine Capital Management LLC boosted its position in shares of XOMA by 3.3% during the first quarter. Stonepine Capital Management LLC now owns 129,813 shares of the biotechnology company’s stock worth $2,587,000 after acquiring an additional 4,113 shares during the last quarter. Nuveen LLC bought a new position in shares of XOMA during the first quarter worth $286,000. Deutsche Bank AG grew its stake in XOMA by 5,087.9% during the first quarter. Deutsche Bank AG now owns 6,433 shares of the biotechnology company’s stock valued at $128,000 after acquiring an additional 6,309 shares in the last quarter. Finally, CM Management LLC increased its holdings in XOMA by 16.4% in the 1st quarter. CM Management LLC now owns 64,000 shares of the biotechnology company’s stock valued at $1,276,000 after acquiring an additional 9,000 shares during the last quarter. 95.92% of the stock is currently owned by institutional investors.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.